6-(2-溴乙酰基)吡啶甲酸 | 160322-90-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-(2-溴乙酰基)吡啶甲酸
• 英文名称: 6-(2-Bromoacetyl)pyridine-2-carboxylic acid
• CAS: 160322-90-7
• 化学式: C₈H₆BrNO₃
• 分子量: 244.045
• InChiKey: LGCXZJONSFPMMR-UHFFFAOYSA-N

物化性质

• 沸点：
  405.5±35.0 °C(Predicted)
• 密度：
  1.744±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  67.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(2-溴乙酰基)吡啶甲酸 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 8.0h， 生成 6-(2-(3,4-二乙氧基苯基)噻唑-4-基)甲酸吡啶
  参考文献：
  名称：

  Novel Thiazole Derivatives as Inhibitors of Superoxide Production by Human Neutrophils: Synthesis and Structure-Activity Relationships

  摘要：

  Neutrophils have an important role in the self-defense systems of organisms through the production of superoxide. On the other hand, it has been proposed that abnormal amounts of superoxide produced by neutrophils are a serious factor in tissue injury. A series of novel thiazole derivatives was prepared and evaluated inhibitory effect on superoxide production by human neutrophils in vitro. Among these compounds, 6-[2-(3,4-diethoxyphenyl)thiazol-4-yl]-pyridine-2-carboxylic acid (OPC-6535) was selected as one of the most promising compounds. The synthesis and structure-activity relationships of these compounds are reported herein.

  DOI：

  10.1021/jm00002a017
• 作为产物：
  描述：

  6-乙酰基-2-吡啶羧酸 在 溴 作用下， 以 溶剂黄146 为溶剂， 反应 0.17h， 生成 6-(2-溴乙酰基)吡啶甲酸
  参考文献：
  名称：

  Novel Thiazole Derivatives as Inhibitors of Superoxide Production by Human Neutrophils: Synthesis and Structure-Activity Relationships

  摘要：

  Neutrophils have an important role in the self-defense systems of organisms through the production of superoxide. On the other hand, it has been proposed that abnormal amounts of superoxide produced by neutrophils are a serious factor in tissue injury. A series of novel thiazole derivatives was prepared and evaluated inhibitory effect on superoxide production by human neutrophils in vitro. Among these compounds, 6-[2-(3,4-diethoxyphenyl)thiazol-4-yl]-pyridine-2-carboxylic acid (OPC-6535) was selected as one of the most promising compounds. The synthesis and structure-activity relationships of these compounds are reported herein.

  DOI：

  10.1021/jm00002a017

文献信息

• Tetomilast Polymorphs
  申请人：Aoki Satoshi

  公开号：US20100222590A1

  公开（公告）日：2010-09-02

  The present invention provides a tetomilast crystal that is industrially easily produced in a large volume. (1) a tetomilast hydrate crystal having a powder X-ray diffraction spectrum that is substantially the same as the powder X-ray diffraction spectrum shown in FIG. 2 ; (2) an anhydrous tetomilast type A crystal having a powder X-ray diffraction spectrum that is substantially the same as the powder X-ray diffraction spectrum shown in FIG. 4 ; (3) an anhydrous tetomilast type C crystal having a powder X-ray diffraction spectrum that is substantially the same as the powder X-ray diffraction spectrum shown in FIG. 8 ; (4) a tetomilast acetonitrile solvate crystal having a powder X-ray diffraction spectrum that is substantially the same as the powder X-ray diffraction spectrum shown in FIG. 10 ; and (5) a mixture consisting of the above anhydrous tetomilast type A crystal and an anhydrous tetomilast type B crystal. These crystals are stable towards heat and moisture, and are also excellent in terms of the disintegration property and dissolution property of tablets. Accordingly, these crystals are preferably used as pharmaceutical compositions.

  本发明提供一种工业上易于大量生产的tetomilast晶体。(1) 一种tetomilast水合物晶体，其粉末X射线衍射谱与图2所示的粉末X射线衍射谱基本相同；(2) 一种无水tetomilast A型晶体，其粉末X射线衍射谱与图4所示的粉末X射线衍射谱基本相同；(3) 一种无水tetomilast C型晶体，其粉末X射线衍射谱与图8所示的粉末X射线衍射谱基本相同；(4) 一种tetomilast乙腈溶剂晶体，其粉末X射线衍射谱与图10所示的粉末X射线衍射谱基本相同；以及(5) 由上述无水tetomilast A型晶体和无水tetomilast B型晶体组成的混合物。这些晶体对热和湿度稳定，并且在片剂的分散性和溶解性方面也表现出色。因此，这些晶体最好用作制药组合物。
• Tetomilast polymorphs
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP2206711A2

  公开（公告）日：2010-07-14

  The present invention provides a tetomilast crystal that is industrially easily produced in a large volume. (1) a tetomilast hydrate crystal having a powder X-ray diffraction spectrum having characteristic peaks at 2θ = 10.6°, 12.9°, 21.1°, 22.3° and 25.0°; (2) an anhydrous tetomilast type C crystal having a powder X-ray diffraction spectrum having characteristic peaks at 2θ = 4.2°, 8.2°, 12.0°, 16.4°, 24.7° and 25.9°; (3) a tetomilast acetonitrile solvate crystal having a powder X-ray diffraction spectrum having characteristic peaks at 2θ = 3.6°, 7.1°, 10.6°, 14.2° and 24.8°. These crystals are stable towards heat and moisture, and are also excellent in terms of the disintegration property and dissolution property of tablets. Accordingly, these crystals are preferably used as pharmaceutical compositions.

  本发明提供了一种易于在工业上大量生产的四咪唑晶体。(1) 一种水合四美司特晶体，其粉末 X 射线衍射谱在 2θ = 10.6°、12.9°、21.1°、22.3° 和 25.0°处具有特征峰； (2) 一种无水四美司特 C 型晶体，其粉末 X 射线衍射谱在 2θ = 4.2°、8.2°、12.0°、16.4°、24.7° 和 25.9°处具有特征峰。2°、8.2°、12.0°、16.4°、24.7°和 25.9°；(3) 一种乙腈溶解的四氟司特晶体，其粉末 X 射线衍射谱在 2θ = 3.6°、7.1°、10.6°、14.2°和 24.8°处有特征峰。这些晶体对热和湿度稳定，在片剂的崩解性能和溶解性能方面也非常出色。因此，这些晶体最好用作药物组合物。
• J. Med. Chem. 1995, 38, 353-358
  作者：

  DOI：——

  日期：——
• TETOMILAST POLYMORPHS
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP1999128A1

  公开（公告）日：2008-12-10
• Tetomilast polymorph
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP2206711B1

  公开（公告）日：2012-08-22